Stokes Capital Advisors LLC grew its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 8.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,006 shares of the conglomerate's stock after acquiring an additional 1,593 shares during the quarter. Stokes Capital Advisors LLC's holdings in Danaher were worth $4,592,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of the stock. Decker Retirement Planning Inc. acquired a new stake in Danaher during the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher during the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher during the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC purchased a new position in Danaher in the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in Danaher during the third quarter worth approximately $55,000. 79.05% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
DHR has been the topic of several recent research reports. Citigroup reduced their target price on shares of Danaher from $305.00 to $285.00 and set a "buy" rating on the stock in a report on Monday, January 6th. Wolfe Research raised Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 target price for the company in a research report on Thursday, October 31st. Guggenheim assumed coverage on Danaher in a research report on Thursday, December 19th. They set a "buy" rating and a $275.00 price target on the stock. Scotiabank began coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a "sector perform" rating and a $265.00 price objective for the company. Finally, Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $286.80.
Read Our Latest Research Report on DHR
Danaher Price Performance
Shares of NYSE DHR traded down $3.49 during midday trading on Monday, reaching $238.41. The company's stock had a trading volume of 3,044,734 shares, compared to its average volume of 2,640,177. The company has a market cap of $172.20 billion, a price-to-earnings ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average price of $234.85 and a 200 day moving average price of $253.51. Danaher Co. has a one year low of $222.53 and a one year high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business's revenue for the quarter was up 3.1% on a year-over-year basis. During the same period last year, the company posted $2.02 earnings per share. On average, equities research analysts expect that Danaher Co. will post 7.49 EPS for the current year.
Danaher Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher's dividend payout ratio is currently 20.61%.
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
